Major breakthroughs in dementia and tau research, alongside advances in diagnostic biomarkers and clinical outcomes across multiple disease areas

A $100 million global trial will test whether adding metabolism-targeting therapy to lifestyle interventions can further reduce cognitive decline risk in older adults, representing a significant investment in dementia prevention research.

The investigational drug diranersen demonstrated the first clinical evidence that targeting tau protein may slow cognitive decline, with the lowest dose showing the most consistently positive effects in clinical trials.

Fecal biomarkers including eosinophil-derived neurotoxin, lipocalin-2, and calprotectin can distinguish pediatric inflammatory bowel disease from acute diarrhea, with calprotectin proving most effective for differentiation.

Experts recommend high suspicion and testing for cyclosporiasis as outbreak patterns shift, emphasizing the importance of parasite detection in clinical practice.

Holmium laser enucleation of the prostate demonstrates safety and effectiveness for treating patients with recurrent benign prostatic obstruction, offering an alternative procedural option.

Hispanic and Asian populations in the US face clinically meaningful risk for noncardia gastric cancer up to two decades earlier than non-Hispanic White populations, highlighting significant ethnic health disparities.

Prior authorization delays for age-related macular degeneration drugs cause vision loss in only a small portion of patients, suggesting delays are harmless for most individuals with this condition.

Thyroid dysfunction is associated with higher long-term mortality risk in patients with heart failure and mildly reduced ejection fraction, indicating a need for thyroid monitoring in cardiac patients.